Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

Completed · Phase 3

Conditions studied: Persistent Nonvalvular Atrial Fibrillation

In brief

This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation

Key facts

Study ID

NCT00171769

Run by

Novartis

People needed

200

Starts

2005-04-01

Last updated by the study team

2017-02-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• persistent AF (electrical cardioversion is planned)
• written informed consent

You may not qualify if…

• acute clinical signs of venous thromboembolism
• current oral anticoagulation
• indication for medical cardioversion

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• Study site — Investigative Centers, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.